What Baxter's Quarter ended Sep 30, 2026 10-Q says: 5 signals
Baxter filed its latest 10-Q with the SEC on Oct 29, 2026. It discusses compliance burden, digital transformation and product liability.
Public (BAX)Medical Equipment Manufacturing10,000+ employeesbaxter.comLinkedIn
Get Baxter's live signals in Claude or ChatGPT, or by API
What changed at Baxter this week? Use Autobound signals for baxter.com.- Filed
- Oct 29, 2026
- Period
- Quarter ended Sep 30, 2026
- Filings
- 3
- Signals
- 17
Source: Autobound Signal API · 62 signals tracked for Baxter · updated
10-Q · latest 10
What Baxter's 10-Q filings say
- SEC EDGAR
10-Q · Quarter ended Sep 30, 2026
Filed · 5 signals
Baxter halted Novum LVP distribution following FDA Class I recall classification
The FDA classified Baxter's voluntary corrections for the Novum LVP as Class I recalls, prompting a temporary stop on distribution and installation in the U.S.
Baxter reorganizes business into two reportable segments under a new operating model
In Q2 2026, Baxter implemented a new operating model, consolidating its structure into two segments: Medical Products & Therapies and Healthcare Systems & Technologies, while folding Pharmaceuticals into Infusion Therapies & Platforms.
Baxter incurs $54 million YTD for enterprise-wide systems modernization and digital capabilities
Baxter recorded $20 million in Q3 2026 and $54 million for the first nine months of 2026 in business transformation costs for enterprise-wide initiatives to modernize systems and enhance digital capabilities.
$54M
business transformation costs for enterprise-wide initiatives to modernize and simplify systems and enhance digital capabilities
Baxter reports injectables sales headwinds and supply chain constraints across international markets
Baxter experienced lower sales in its Injectables portfolio during the first nine months of 2026 due to ongoing supply constraints across U.S.
Baxter incurred $3M in Q3 2026 complying with EU medical devices regulations
Baxter recorded $3 million in Q3 2026 and $11 million year-to-date in third-party and contractor costs to comply with the European Union's medical device regulations for previously registered products.
$3M
incremental costs to comply with European Union medical device regulations in Q3 2026
- SEC EDGAR
10-Q · Quarter ended Jun 30, 2026
Filed · 6 signals
FDA Class I recall halts Novum LVP distribution with remediation costs and write-downs
Baxter stopped distributing and installing its Novum LVP in the U.S.
Baxter implements new operating model in Q2 2026, consolidating into two reportable segments
Baxter implemented a new operating model during Q2 2026 to align decision-making and commercial execution, consolidating its operations into two segments: Medical Products & Therapies and Healthcare Systems & Technologies.
Baxter reports $75 million in six-month business optimization charges following Kidney Care sale
Baxter recorded business optimization charges of $7 million in Q2 2026 and $75 million in the first six months of 2026 to right-size its cost structure post-divestiture.
$75M
business optimization and restructuring charges in the first six months of 2026
Gross margin ratio decreased by 2.1 percentage points excluding special items in Q2 2026
Baxter's adjusted gross margin contracted by 2.1 percentage points in Q2 2026 due to higher manufacturing and supply costs, capitalized indirect costs, and product mix.
-2.1%
adjusted gross margin ratio decrease for the second quarter of 2026
Baxter reported ongoing supply constraints in U.S.
$6M
Hurricane Helene costs including remediation, air freight and other costs for the six months ended June 30, 2026
Earlier 10-Q filings
- 10-Q · Quarter ended Mar 31, 2026Filed · 6 signalsSEC EDGAR
Showing 10 of 17 filing signals. The Signal API returns all of them.
Get them with one API callEarnings calls
Baxter earnings headlines
From earnings call transcripts (Signal API type earnings-transcripts).
| Call date | What the company said |
|---|---|
| FDA warning letter prompts Round Lake facility manufacturing repositioningThe company received an FDA warning letter following an inspection at its Round Lake, Illinois facility, creating operational disruption and compliance requirements. In response, management is discontinuing its cephalosporin product line to simplify site operations and address inspection observations. This presents opportunities for regulatory compliance, quality management, and cleanroom... | |
| New Chief Financial Officer appointed to lead business turnaroundJohn Rogers joined as Executive Vice President and Chief Financial Officer on October 1, bringing operational turnaround experience. Leadership transitions at the CFO level often trigger comprehensive vendor reviews, budget audits, and adjustments to capital allocation. Rogers emphasized plans to evaluate capital allocation policies, cost structures, and operational efficiencies. | |
| Cephalosporin production discontinued incurring $39M restructuring costManagement decided to terminate cephalosporin manufacturing at its Round Lake facility, incurring $39 million in restructuring costs in Q3. The discontinued product lines represent $50 million in revenue and $30 million in operating income in 2026. This operational restructuring streamlines the facility exclusively for non-cephalosporin production while leaving customers supported under... | |
| Injectables growth impacted by contract manufacturing supply disruptionsThird-quarter injectables performance was negatively affected by supply challenges originating from an outsourced contract manufacturer. While management noted sequential improvement, the issue caused headwind earlier in the year and required dedicated intervention to mitigate. Solutions around contract manufacturing oversight, supplier risk management, and track-and-trace monitoring are... | |
| Fragmented IT application landscape targets standardization and rationalizationIncoming CFO John Rogers identified embedded complexity across IT and finance functions, specifically pointing out an excessive number of disparate applications. Management intends to simplify and standardize non-standard operational processes and application sprawl over the next 1 to 3 years. Enterprise software vendors offering ERP consolidation, IT service management, and application... | |
| Over 700 continuous improvement initiatives deployed across operationsThe company has integrated its continuous improvement operating system, completing over 700 initiatives year-to-date with 200 in flight and 350 planned. Operational wins include cutting blood pressure cuff cycle times by over 10% and reducing alternate shipment back orders by over 50%. This ongoing push creates opportunities for industrial engineering, lean manufacturing, and workflow... |
Signal API · MCP
Track Baxter with the Signal API
One POST /v1/companies/enrich call with baxter.com returns Baxter 10-Q signals (sec-10q), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"baxter.com","signal_types":["sec-10q"],"limit":20}'Bulk data
Need this signal for 10,000+ companies?
Get a free sample file or a bulk feed (API, GCS push, flat file). The sample is real 10-Q Filings records, as a CSV.
Same industry
10-Q at related companies
Questions about Baxter 10-Q
When did Baxter file its latest 10-Q?
What did Baxter disclose in its latest 10-Q?
What did Baxter say on its recent earnings calls?
Where can I read Baxter's 10-Q filing?
Page updated , the date of the newest row on this page.
Source. Quarterly reports (Form 10-Q) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .